Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sawai Preparing to File More Products for US Approval: Exec
July 4, 2014
- Santen to Complete Acquisition of Ophthalmology Assets from Merck
July 4, 2014
- Taiho Submits Application for Additional Indication of Febrile Neutropenia for Zosyn
July 4, 2014
- BMKK Asks Major Law Firm to Conduct Independent Investigation of Clinical Research on Sprycel
July 4, 2014
- Kyowa Kirin to Resume Development of Bardoxolone Methyl for CKD Patients with Type 2 Diabetes
July 4, 2014
- Poteligeo Re-Filed for Approval of Additional Indication of Untreated CCR4-Positive ATL
July 3, 2014
- Meiji Seika Pharma Wants to Make Cancer Drugs, Biologics 4th Biz Pillar
July 3, 2014
- Genzyme Japan Submits NDA for Oral Gaucher’s Disease Drug
July 3, 2014
- CMIC, JSR Set Up Joint Venture for Next-Generation Antibodies
July 3, 2014
- MTPC Plans Entry into Global Vaccine Business Starting with a Seasonal Influenza Vaccine
July 3, 2014
- Hospira Japan Appoints Former Mundipharma President Toyohara as Its New President
July 3, 2014
- Sawai, MTPC Agree on Transfer of Kashima Plant to Sawai
July 3, 2014
- Takeda Sets Up Japan Vaccine Unit Led by Ex-Sanofi R&D Head
July 2, 2014
- Pfizer Japan to Diversify Revenue Streams to Maintain Growth in “Post-Lipitor Era”: President
July 2, 2014
- Sumitomo Dainippon Transfers Marketing Rights to 3 Brands Including Inteban to Teikoku Seiyaku
July 2, 2014
- Sanofi Ties Up with Japanese Bioventure for Development of Transdermal Patch Formulation of Lyxumia
July 2, 2014
- Dr Morich’s 900 Million Yen Exec Pay Highest in Takeda
July 1, 2014
- Sanofi, Takeda Team Up to Raise Awareness of Diabetes
July 1, 2014
- Teijin Licenses ADA Deficiency Treatment from Sigma-Tau Pharma
July 1, 2014
- Gilead Submits NDA for HCV Treatment Sofosbuvir in Japan
July 1, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…